Jennifer A. Maynard
0000-0002-0363-8486
Publication & Citation Trends
Publications
0 total
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.
Cited by 2
Semantic Scholar
Abstract 2659: CD44v9-targeted antibody-drug conjugate as a novel therapy for advanced breast cancer
Cited by 0
Semantic Scholar
Abstract PD3-11: Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy
Cited by 0
Semantic Scholar
Treatment of murine autoimmune myocarditis with a novel monoclonal antibody that targets multiple inflammatory pathways
Cited by 0
Semantic Scholar
Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.
Cited by 0
Semantic Scholar
CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer.
Cited by 0
Semantic Scholar
SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics OA
Cited by 7
Semantic Scholar
Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV
Cited by 1
Semantic Scholar
Research Topics
Monoclonal and Polyclonal Antibodies Research
(45)
Bacterial Infections and Vaccines
(23)
Protein purification and stability
(18)
SARS-CoV-2 and COVID-19 Research
(16)
Bacteriophages and microbial interactions
(15)
Affiliations
University of Minnesota
March of Dimes
Howard Hughes Medical Institute
University of California, Irvine
Washington University in St. Louis